Strategic partnerships Potential collaborations with global biotech and pharma players focusing on peripheral neuropathies could accelerate clinical development and expand geographic reach, especially leveraging Regenacy's China joint venture with 3E Bioventures.

HDAC6 leverage Ricolinostat’s novel HDAC6 selective mechanism offers a differentiated therapeutic approach for diabetic, chemotherapy-induced, and inherited peripheral neuropathies, creating multiple potential licensing or co-development opportunities.

Clinical expansion Advancing ricolinostat into Phase 2 and pursuing trials in diverse peripheral neuropathy indications presents a clear path for partners to join in late-stage development or commercial-stage access programs.

Early-stage footprint Small company size with recent Series A funding signals a need for strategic investors or contract development & manufacturing partners to support scale-up, regulatory planning, and global trials.

CMT and CMTA ties Existing collaborations with Charcot-Marie-Tooth associations suggest avenues for co-development, patient recruitment, and real-world data partnerships to de-risk clinical programs and enhance outcomes evidence.